Cas:21300-54-9 Methyl (2H3)acetate manufacturer & supplier

Chemical Name:Methyl (2H3)acetate

CAS.NO:21300-54-9

Synonyms:Methyl (H)acetate;Acetic-d acid, methyl ester

Molecular Formula:C₃H₃D₃O₂

Molecular Weight:77.097

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:44.0±3.0 °C at 760 mmHg

Density:0.9±0.1 g/cm3

Index of Refraction:1.354

PSA:26.30000

Exact Mass:77.055611

LogP:0.18

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Methyl (H)acetate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Acetic-d acid, methyl ester physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Methyl (H)acetate Use and application,Methyl (H)acetate technical grade,usp/ep/jp grade.

Related News: Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching. Methyl (2H3)acetate manufacturer The Ministry of Agriculture said late Saturday that a fresh outbreak of a lethal form of influenza had been found in poultry in the southern province of Hunan, and that officials had ordered the slaughter of 17,828 chickens. Methyl (2H3)acetate supplier Their pharmacological activity plays a direct role in the diagnosis, cure, mitigation, treatment, or prevention of disease. Methyl (2H3)acetate vendor A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting. Methyl (2H3)acetate factory A combination of Imbruvica and AbbVie and Roche’s Venclexta slashed the risk of cancer progression or death by 78.4% compared with a cocktail of Roche’s Gazyva and the chemotherapy chlorambucil in previously untreated CLL. The data, from the phase 3 GLOW trial, were shared at the European Hematology Association (EHA) annual meeting.